Table 5:
Outcomes for Participants with an Adequate Trial of an Effective Medication for PTSD plus Outcomes Measurement (Weighted)
| Agent | Fluoxetine | Paroxetine | Sertraline | Topiramate | Venlafaxine | Pairwise Differences |
|---|---|---|---|---|---|---|
| n=659 | n=328 | n=1,376 | n=105 | n=463 | ||
| Raw Outcomes | ||||||
| Baseline PCL, M (SD) | 61.9 (12.1) | 62.0 (12.1) | 62.0 (11.9) | 62.7 (16.0) | 62.3 (12.3) | No Differences |
| Change in PCL, M (SD) | -5.8 (14.4) | -5.6 (15.4) | -6.0 (14.6) | -5.0 (22.1) | -5.1 (14.4) | No Differences |
| 5-Point Drop in PCL, % (n) | 51.1 (342) | 50.2 (167) | 49.7 (689) | 40.4 (45) | 48.3 (222) | No Differences |
| 10-Pt. Drop plus Loss of Diagnosis, % (n) | 17.3 (116) | 19.3 (67) | 17.3 (237) | 15.5 (17) | 14.2 (63) | No Differences |
| Symptom Clusters | ||||||
| Baseline Reexperiencing, M (SD) | 17.7 (4.4) | 17.8 (4.2) | 17.8 (4.2) | 17.5 (7.0) | 17.8 (4.4) | No Differences |
| Change in Reexperiencing, M (SD) | -1.6 (4.9) | -1.6 (5.1) | -1.6 (4.9) | -1.0 (8.6) | -1.2 (5.0) | No Differences |
| Baseline Avoidance, M (SD) | 7.6 (2.0) | 7.7 (1.9) | 7.6 (2.0) | 7.6 (2.7) | 7.5 (2.1) | No Differences |
| Change in Avoidance, M (SD) | -0.7 (2.5) | -0.8 (2.7) | -0.8 (2.6) | -0.6 (3.6) | -0.6 (2.4) | No Differences |
| Baseline Numbing, M (SD) | 17.2 (4.4) | 17.0 (4.3) | 17.2 (4.5) | 18.0 (5.2) | 17.4 (4.5) | No Differences |
| Change in Numbing, M (SD) | -1.6 (5.0) | -1.3 (5.3) | -1.7 (5.2) | -2.0 (8.2) | -1.5 (5.3) | No Differences |
| Baseline Hyperarousal, M (SD) | 19.4 (4.1) | 19.4 (4.2) | 19.4 (3.8) | 19.7 (5.8) | 19.6 (4.1) | No Differences |
| Change in Hyperarousal, M (SD) | -1.8 (4.8) | -1.7 (4.8) | -1.9 (4.7) | -1.7 (7.3) | -1.9 (4.9) | No Differences |
| Baseline Sleep, M (SD) | 7.4 (2.0) | 7.6 (1.9) | 7.5 (1.9) | 7.3 (3.3) | 7.5 (2.1) | No Differences |
| Change in Sleep, M (SD) | -0.7 (2.3) | -0.7 (2.2) | -0.7 (2.3) | -0.4 (3.8) | -0.6 (2.5) | No Differences |
Note. PTSD=Posttraumatic Stress Disorder, PCL=PTSD Checklist, M=mean, SD=standard deviation